Who is sponsoring NCT06666439?

NCT06666439 is sponsored by Julia Foldi.

What drugs are being tested in NCT06666439?

Interventions in NCT06666439: circulating tumor DNA (ctDNA).

What condition does NCT06666439 study?

NCT06666439 studies Metastatic Invasive Lobular Carcinoma (mILC).

Is NCT06666439 still recruiting?

NCT06666439 is currently recruiting now. Last updated 20 January 2026.

Last reviewed 2026-01-20 · How we verify

NCT06666439: LBC-Monitor

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer

Recruiting now Last updated 20 January 2026

What this trial tests

trial testing circulating tumor DNA (ctDNA) in Metastatic Invasive Lobular Carcinoma (mILC) in 20 participants. Currently enrolling.

Timeline

12 December 2024

Primary endpoint
31 October 2029

31 October 2029

Quick facts

Lead sponsor	Julia Foldi
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	20
Start date	12 December 2024
Primary completion	31 October 2029
Estimated completion	31 October 2029
Sites	1 location across United States

Drugs / interventions tested

circulating tumor DNA (ctDNA)

Conditions studied

Metastatic Invasive Lobular Carcinoma (mILC) — all drugs for Metastatic Invasive Lobular Carcinoma (mILC) →

Sponsor

Julia Foldi

Who can join

18 and older, female only, with Metastatic Invasive Lobular Carcinoma (mILC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to characterize early dynamic changes in ctDNA, which can aid in tailoring early therapy in patients with metastatic Invasive lobular carcinoma (ILC). Response assessment using ctDNA analysis could not only aid in de-escalation but also escalation strategies.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Unique Molecular Alteration of Lobular Breast Cancer: Association with Pathological Classification, Tumor Biology and Behavior, and Clinical Management.
Zhang H, Peng Y. · · 2025 · cited 5× · PMID 39941785 · DOI 10.3390/cancers17030417
Liquid biopsy in breast cancer: Redefining precision medicine.
Schiavone ML, Scarpitta R, Ravera F, Bleve S, et al · · 2025 · cited 3× · PMID 40740670 · DOI 10.1016/j.jlb.2025.100312

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06666439 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Julia Foldi
Last refreshed: 20 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06666439.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing